Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-15
2006-08-15
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S300000
Reexamination Certificate
active
07091182
ABSTRACT:
A novel relationship between pancreatico-biliary secretion and autistic syndrome is disclosed. This relationship enables a novel therapy for the treatment of the symptoms of autistic syndromes, comprising the administration of a therapeutically effective, preferably intravenous, dose of secretin to an individual with autistic syndrome. The relationship further enables a differential diagnosis for autistic syndrome, comprising an analysis of an individual's blood and/or intestinal tissue for the presence of secretin and comparison of the level of secretin to known norms.
REFERENCES:
patent: 3833722 (1974-09-01), Graybill et al.
patent: 3940480 (1976-02-01), Suenaga et al.
patent: 3987014 (1976-10-01), Guiducci
patent: 4086220 (1978-04-01), Schlatter
patent: 4098779 (1978-07-01), König
patent: 4302448 (1981-11-01), Bickel
patent: 4462991 (1984-07-01), Higuchi et al.
patent: 4533494 (1985-08-01), Uchiyama
patent: 4711847 (1987-12-01), König
patent: 4778794 (1988-10-01), Naruse et al.
patent: 4806336 (1989-02-01), Carlquist et al.
patent: 4920122 (1990-04-01), Naruse et al.
patent: 4994467 (1991-02-01), Zimmerman
patent: 5008251 (1991-04-01), Gruber
patent: 5094837 (1992-03-01), Bis
patent: 5225407 (1993-07-01), Oakley et al.
patent: 5380872 (1995-01-01), Sugg et al.
patent: 5527825 (1996-06-01), Karson et al.
patent: 5686311 (1997-11-01), Shaw
patent: 6020310 (2000-02-01), Beck et al.
patent: 6197746 (2001-03-01), Beck et al.
patent: 6498143 (2002-12-01), Beck et al.
patent: 6790825 (2004-09-01), Beck et al.
patent: WO 94/16756 (1994-04-01), None
patent: WO 96/06635 (1996-07-01), None
patent: WO 98/52593 (1998-11-01), None
patent: WO 99/10361 (1999-12-01), None
Anderson et al., “Whole blood serotonin in autistic and normal subjects”,J. Child Psychology&Psychiatry&Allied Disciplines, 1987; 28(6):885-900.
Bachevalier et al., “The contribution on medial temporal lobe structures in infantile autism: a neurobehavioral study in primates”, inThe Neurobiology of Autism, Bauman and Kemper (editors), The Johns Hopkins Press, Baltimore, 1994, 1994:146-69.
Bauman et al, “Histoanatomic observations of the brain in early infantile autism”,Neurology, 1985; 35(6):866-74.
Bauman et al., “Neuroanatomic observations of the brain in autism” inThe Neurobiology of Autism, Bauman and Kemper (editors), The John Hopkins Press, Baltimore, 1994, 1994:119-45.
Beck, “Dateline,” NBC television program, Oct. 7, 1998 (videotape available from Autism Research Institute, 4182 Adams Avenue, San Diego, CA 92116, www.autism.com/ari).
Beck, “Good Morning America” ABC television program, (videotape available from Autism Research Institute 4182 Adams Avenue, San Diego, CA 92116, www.autism.com/ari).
Beck, “Transdermal Secretin and Other Approach,” (letter to www.healthboards.com/autism/1089.html) Secretin Talk@Onelist.com (Dec. 30, 1998).
Binstock, secretin, email to newsgroup bit.listserv.autism (Aug. 23, 1996).
Binstock, Secretin, email to newsgroup bit.listserv.autism (Sep. 26, 1996).
Bouvard et al., “Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study”,Psychiatry Research, 1995; 58(3):191-201.
Carlton, About Dr. Shaw's Book-Careful Venting Post!, email to newsgroup bit.listserv.autism (Jan. 21, 1998).
Carlton, Dr. Shaw's Book arrived Today!, email to newsgroup bit.listserv.autism (Jan. 20, 1998).
Carlton, Secretin “gushing,” email to newsgroup bit.listserv.autism (Jan. 22, 1998).
Carlton, The Hypothalamus-specific peptides, email to newsgroup bit.listserve.autism (Jan. 19, 1998).
Charlton et al., “Secretin immunoreactivity in rat and pig brain”,Peptides, 1981; 2 suppl 1:45-9.
Chez et al.,Journal of Autism and Developmental Disorders, vol. 30, No. 2, pp. 87-94.
Conaty, Pancreatic Lipase deficiency, email to newsgroup bit.listserv.autism (Aug. 26, 1996).
Conaty, Secretin email to newsgroup bit.listserv.autism (Aug. 25, 1996).
Conn's Current Therapy, Robert E. Pakel Editor, p. 452 W.B. Saunders Co. Philadelphia, PA.
Cook et al., “The Serotonin System in Autism”,Current Opinion in Pediatrics, 8:348-354, (1996).
Dawson et al., “Subgroups of autistic children based on social behavior display distinct patterns of brain activity”,Journal of Abnormal Child Psychology, 1995; 23(5):569-83.
Dollinger et al., “Effects of Secreting and Cholecystokinin on Motor Activity of Human Jejunum”,Digestion12:1975, pp. 9-16.
El-Salhy et al., “Immunohistochemical evidence of gastro-entero-pancreatic neurhormonal peptides of vertebrate type in the nervous system of the larva of a dipteran insect, the Hoverfly,Eristalis Aeneus”, Regulatory Peptides1:1980, pp. 187-204.
Fara et al., “Effect of secretin and cholecystokinin on small intestinal blood flow distribution”,Am. J. Physiology, 1975; 229(5):1365-70.
Fremeau et al., “Secretin stimulates cyclic AMP formation in the rat brain”,Journal of Neurochemistry, 1986; 46(6):1947-55.
Fremeau et al., “Secretin: Specific Binding to Rat Brain Membranes”;The Journal of Neuroscience, vol. 3, No. 8, pp. 1620-1625 (1983).
Garnier et al., “Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children”,J. Autism&Developmental Disorders, 1988; 16(1):23-9.
George et al., “Cerebral blood flow abnormalities in adults with infantile autism”,Journal of Nervous&Mental Disease, 1992; 180(7):413-7.
Harteveld et al., “Autism Role of Drug Treatment and a Guide to its Use”,CNS Drugs, 8(3):227-236, (1997).
Hays, Digestion—CCK/Acetylcholine email to newsgroup bit listserv autism (Mar. 27, 1997).
Horvath et al.,Journal of Pediatrics, vol. 135, No. 5, pp. 559-563.
Horvath et al., “Improved Social and Language Skills After Secretin Administration in Patients with Autistic Spectrum Disorders”,Assoc. Acad. Minority Physicians, 9(1):9-15 (1998).
Horvath et al., “Secretin Therapy—The Child Psychologist”,Journal of the Association for Academic Minority Physicians, 9(1):9-15 (1998). Retrieved from the Internet: URL:http://www.childpsychology, com/autism/secretin.htm.
Horvath et al.,Journal of Pediatrics, vol. 135, No. 5, pp. 559-563.
Itoh et al., “The secretin precursor gene: structure of the coding region and expression in the brain”,J. Biological Chemistry, 1991; 266(19):12595-8.
Karelson et al., “Regulation of Adenylate Cyclase by Galanin, Neuropeptide Y, Secretin and Vasoactive Intestinal Polypeptide in Rat Frontal Cortex, Hippocampus and Hypothalamus”;Neuropeptides, vol. 28, pp. 21-28 (1995).
Kimura et al., “Effects of preoptic injections of gastrin, cholecystokinin, secretin, vasoactive intestinal peptide and PHI on the secretin of luteinizing hormone and prolactin in ovariectomized estrogen-primed rats”,Brain Research, 1987; 410(2):315-22.
Lawrence et al., “Effect of secretin on intestinal lymph flow and composition in the rat”,Quarterly J. Experimental Physiology, 1981; 66(3):297-305.
Lebenthal et al., “Immunoglobin concentrations in the duodenal fluids of infants and children” II. The Effect of pancreosymin and secretin.Am. J. Gastroenterology, 1981; 75(6):436-9.
Leiter et al., “Secretin”,Gut peptides: Biochemistry and Physiologyedited by Walsh and Dockray, Raven Press, Ltd., New York, 1994: 147-93.
Lenzen et al., “Secretin stimulates bile ductular secretory activity through the camp system”,American Journal of Physiology, 1992; 263(4 pt 1):G527-32.
Mayberry, Canadian listmates, email to newsgroup bit.listserv.autism (Sep. 20, 1996).
Mayberry, Measles and Substance P, email to newsgroup bit.listserve.autism (Feb. 10, 1997).
Mayberry, Peptide Homone, Substance P, email to newsgroup bit.listserv.autism (Oct. 16, 1996).
Mayberry, Secretin Salve, email to newsgroup bit.listserv.autism (Jul. 17,
Beck Victoria
Horvath Karoly
Carlson Karen Cochrane
Fish & Richardson P.C.
Repligen Corporation
LandOfFree
Method for assisting in differential diagnosis and treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for assisting in differential diagnosis and treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for assisting in differential diagnosis and treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3653709